Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 4 July (HL8857), whether patient groups were consulted in relation to the discussions on Liothyronine (T3) at the meetings of the Regional Medicines Optimisation Committee held in January and May 2018.

The Regional Medicines Optimisation Committees (RMOCs) membership includes patient representation. The comments of patients and of national endocrinology clinical experts have been instrumental in the development of the further advice regarding arrangements for the on-going prescribing of liothyronine. The advice will be shared more widely for comment before being authorised by the RMOCs, including with patient groups and other relevant stakeholders.